#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	13710	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2207	618.5	1	SNP	n	C1184T	0	.	.	1184	1184	C	1459	1459	C	821	C	769	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	13710	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2207	618.5	0	HET	.	.	.	C326T	.	326	326	C	601	601	C	723	C,T	521,160	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24912	23S	2890	2890	99.86	23S.l6.c17.ctg.1	3588	693.0	0	.	n	.	0	T695C	SNP	695	695	T	1031	1031	C	770	C	715	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24912	23S	2890	2890	99.86	23S.l6.c17.ctg.1	3588	693.0	0	.	n	.	0	G1337A	SNP	1337	1337	G	1673	1673	A	832	A,G	783,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24912	23S	2890	2890	99.86	23S.l6.c17.ctg.1	3588	693.0	0	.	n	.	0	T1971C	SNP	1971	1971	T	2307	2307	C	752	C	692	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24912	23S	2890	2890	99.86	23S.l6.c17.ctg.1	3588	693.0	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	2933	2933	T	764	T,C	718,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24912	23S	2890	2890	99.86	23S.l6.c17.ctg.1	3588	693.0	1	SNP	n	A2045G	0	.	.	2045	2045	A	2381	2381	A	791	A	739	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	1940	folP	852	852	100.0	folP.l15.c4.ctg.1	1499	128.8	1	SNP	p	R228S	1	.	.	682	684	AGC	996	998	AGC	190;188;188	A;G;C	172;170;171	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5374	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3272	163.2	1	SNP	p	S91F	0	.	.	271	273	TCC	564	566	TCC	185;185;188	T;C,T;C	176;174,1;178	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5374	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3272	163.2	1	SNP	p	D95N	0	.	.	283	285	GAC	576	578	GAC	188;188;188	G;A;C	178;179;178	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5374	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3272	163.2	1	SNP	p	D95G	0	.	.	283	285	GAC	576	578	GAC	188;188;188	G;A;C	178;179;178	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_M_01390	mtrR.WHO_M_01390	1	1	27	1606	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1295	123.4	1	SNP	p	G45D	1	.	.	133	135	GAC	427	429	GAC	208;206;209	G;A,G;C	194;189,1;196	mtrR.WHO_M_01390:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	798	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	956	82.9	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5138	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2933	174.5	1	SNP	p	D86N	0	.	.	256	258	GAC	597	599	GAC	185;184;186	G;A;C	178;175;177	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5138	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2933	174.5	1	SNP	p	S87I	0	.	.	259	261	AGT	600	602	AGT	185;184;185	A;G;T	175;175;176	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5138	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2933	174.5	1	SNP	p	S87R	0	.	.	259	261	AGT	600	602	AGT	185;184;185	A;G;T	175;175;176	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5138	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2933	174.5	1	SNP	p	S87W	0	.	.	259	261	AGT	600	602	AGT	185;184;185	A;G;T	175;175;176	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5138	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2933	174.5	1	SNP	p	S88P	0	.	.	262	264	TCC	603	605	TCC	185;185;189	T;C;C	174;177;179	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4242	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2682	157.6	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1592	1594	GGC	228;228;225	G;G;C	215;214;211	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	3686	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2364	155.2	1	SNP	p	A311V	0	.	.	931	933	GCA	1266	1268	GCA	218;220;219	G;C;A	203;201;207	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3686	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2364	155.2	1	SNP	p	I312M	0	.	.	934	936	ATC	1269	1271	ATC	216;215;213	A;T;C	198;200;198	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3686	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2364	155.2	1	SNP	p	V316P	0	.	.	946	948	GTG	1281	1283	GTG	215;216;215	G;T;G	203;202;202	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3686	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2364	155.2	1	SNP	p	V316T	0	.	.	946	948	GTG	1281	1283	GTG	215;216;215	G;T;G	203;202;202	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3686	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2364	155.2	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1785	1787	ACC	195;195;193	A;C;C	181;180;178	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3686	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2364	155.2	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1839	1841	GCG	191;190;190	G;C;G	160;141;150	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3686	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2364	155.2	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1839	1841	GCG	191;190;190	G;C;G	160;141;150	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3686	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2364	155.2	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1962	1964	GGC	149;145;148	G;G;C	142;137;139	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3686	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2364	155.2	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1971	1973	GGC	144;145;142	G;G;C	134;130;129	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3686	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2364	155.2	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1989	1991	CCG	120;124;122	C,G;C;G	95,2;99;96	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	5396	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3137	171.5	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1637	1639	CTG	221;220;219	C;T;G	197;197;194	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2442	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1907	127.5	0	.	p	.	0	M83fs	FSHIFT	247	247	A	623	623	C	166	C	151	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	292	porB1a	984	363	90.19	porB1a.l6.c4.ctg.1	1412	20.3	0	.	p	.	0	H217N	NONSYN	649	651	CAT	958	960	AAT	15;15;15	A;A;T	15;15;15	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	292	porB1a	984	363	90.19	porB1a.l6.c4.ctg.1	1412	20.3	0	.	p	.	0	D218N	NONSYN	652	654	GAT	961	963	AAT	15;15;16	A;A;T	14;15;16	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	292	porB1a	984	363	90.19	porB1a.l6.c4.ctg.1	1412	20.3	0	.	p	.	0	A222V	NONSYN	664	666	GCT	973	975	GTT	16;16;17	G;T;T	16;16;17	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	292	porB1a	984	363	90.19	porB1a.l6.c4.ctg.1	1412	20.3	0	.	p	.	0	V226A	NONSYN	676	678	GTA	985	987	GCA	19;20;21	G;C;A	16;19;20	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	292	porB1a	984	363	90.19	porB1a.l6.c4.ctg.1	1412	20.3	0	.	p	.	0	.	MULTIPLE	700	702	ACT	1008	1010	GTA	24;24;23	G;T;A	24;23;22	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	292	porB1a	984	363	90.19	porB1a.l6.c4.ctg.1	1412	20.3	0	.	p	.	0	D238fs	FSHIFT	712	712	G	1020	1020	G	24	G	23	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2574	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1613	158.8	0	.	p	.	0	G38E	NONSYN	112	114	GGA	537	539	GAA	226;222;222	G;A;A	211;207;209	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2574	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1613	158.8	0	.	p	.	0	S46G	NONSYN	136	138	AGC	561	563	GGC	204;200;203	G;G;C	193;190;193	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2574	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1613	158.8	0	.	p	.	0	E48G	NONSYN	142	144	GAA	567	569	GGA	201;202;200	G;G;A	193;196;195	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2574	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1613	158.8	0	.	p	.	0	T87A	NONSYN	259	261	ACT	684	686	GCT	204;204;206	G;C;T	184;186;188	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2574	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1613	158.8	0	.	p	.	0	T89S	NONSYN	265	267	ACC	690	692	AGC	207;204;204	A;G,A;C	185;184,1;183	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2574	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1613	158.8	0	.	p	.	0	.	MULTIPLE	358	359	AA	782	783	CG	189;191	C;G	176;178	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2574	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1613	158.8	0	.	p	.	0	.	MULTIPLE	361	362	GA	785	787	CAG	191;190;191	C;A;G	181;176;177	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2574	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1613	158.8	0	.	p	.	0	N122K	NONSYN	364	366	AAC	789	791	AAA	188;187;188	A;A;A	179;180;180	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2574	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1613	158.8	0	.	p	.	0	K143E	NONSYN	427	429	AAA	852	854	GAA	223;224;226	G;A;A	213;211;211	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2574	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1613	158.8	0	.	p	.	0	V151A	NONSYN	451	453	GTA	876	878	GCA	232;229;232	G;C;A	220;218;220	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2574	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1613	158.8	0	.	p	.	0	Q187R	NONSYN	559	561	CAA	984	986	CGA	220;219;222	C;G;A	201;198;205	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2574	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1613	158.8	0	.	p	.	0	A215T	NONSYN	643	645	GCT	1068	1070	ACT	209;206;206	A,T;C,A;T	193,1;190,1;191	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2574	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1613	158.8	0	.	p	.	0	Y216H	NONSYN	646	648	TAT	1071	1073	CAT	205;204;206	C,T;A;T	190,1;194;195	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2574	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1613	158.8	0	.	p	.	0	I218M	NONSYN	652	654	ATA	1077	1079	ATG	201;202;200	A;T;G,C	189;190;188,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2574	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1613	158.8	0	.	p	.	0	T256A	NONSYN	766	768	ACA	1191	1193	GCA	242;239;238	G;C;A	219;215;218	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2574	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1613	158.8	0	.	p	.	0	W257T	NONSYN	769	771	TGG	1194	1196	ACG	238;235;233	A;C;G	215;215;214	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2574	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1613	158.8	0	.	p	.	0	S258R	NONSYN	772	774	AGT	1197	1199	AGG	232;234;236	A;G;G	212;215;217	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2574	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1613	158.8	0	.	p	.	0	A259V	NONSYN	775	777	GCT	1200	1202	GTT	233;231;231	G;T;T	216;211;213	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2574	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1613	158.8	0	.	p	.	0	L279V	NONSYN	835	837	TTA	1260	1262	GTA	199;197;195	G;T;A,C	178;180;178,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2574	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1613	158.8	0	.	p	.	0	S292T	NONSYN	874	876	TCT	1299	1301	ACT	187;189;189	A;C;T	170;177;178	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2574	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1613	158.8	0	.	p	.	0	H294D	NONSYN	880	882	CAT	1305	1307	GAT	184;185;188	G;A;T	173;174;176	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2574	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1613	158.8	0	.	p	.	0	S295D	NONSYN	883	885	AGT	1308	1310	GAT	186;186;183	G,T,C;A;T	172,1,1;177;175	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2574	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1613	158.8	0	.	p	.	0	Y298H	NONSYN	892	894	TAC	1317	1319	CAC	190;191;190	C;A;C	178;177;180	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2574	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1613	158.8	1	SNP	p	G120K	1	.	.	358	360	AAG	782	784	CGG	189;191;189	C;G;G	176;178;178	porB1b.WHO_L_01891c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2574	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1613	158.8	1	SNP	p	A121D	1	.	.	361	363	GAC	785	788	CGC	191;191;187	C;G;C	181;177;175	porB1b.WHO_L_01891c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2574	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1613	158.8	1	SNP	p	D121N	0	.	.	361	363	GAC	785	788	CGC	191;191;187	C;G;C	181;177;175	porB1b.WHO_L_01891c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	9112	rpoB	4179	4179	100.0	rpoB.l15.c30.ctg.1	4923	184.5	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2112	2114	AAT	166;165;161	A;A;T	164;164;159	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1006	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	958	104.0	1	SNP	p	V57M	1	.	.	169	171	ATG	475	477	ATG	202;203;203	A;T;G	189;188;190	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
